Drug delivery composition, method forming the same and method for treating inner ear disorders

Patent metadata

Field	Value
Publication number	US-12090207-B2
Application number	US-202117379986-A
Country	US
Kind code	B2
Filing date	Jul 19, 2021
Priority date	Feb 26, 2021
Publication date	Sep 17, 2024
Grant date	Sep 17, 2024

Abstract

The disclosure provides a drug delivery composition, method of forming the same and method for treating inner ear disorders. The drug delivery composition includes a temperature sensitive hydrogel, a plurality of microbubbles and a drug. Every microbubble has a protein shell and an inert gas core. These microbubbles are dispersed in the temperature sensitive hydrogel. The drug is dispersed in the temperature sensitive hydrogel. Moreover, the drug delivery composition has a viscosity that can induce cavitation effect.

First claim

What is claimed is:

1. A drug delivery composition, comprising:
a temperature-sensitive hydrogel, wherein the temperature-sensitive hydrogel comprises poloxamer 407, a total weight of the drug delivery composition is 100 percentage by weight, and a content of the poloxamer 407 is no more than 12.5 percentage by weight;
a plurality of microbubbles, wherein each of the plurality of microbubbles has a protein shell and an inert gas core, and the plurality of microbubbles are dispersed in the temperature-sensitive hydrogel, and an amount of the plurality of microbubbles of the drug delivery composition is from about 1×10 8 to about 2×10 10 per mL; and
a drug, dispersed in the temperature-sensitive hydrogel;
wherein the drug delivery composition has a gel-forming temperature, the gel-forming temperature is greater than 25° C., the drug delivery composition has a viscosity for inducing cavitation effect of ultrasound before gel-forming and forms a fixed gel at a body temperature of a subject, and the viscosity for inducing cavitation effect is from about 0.01 Pa·S to about 1.3846 Pa·S.

2. The drug delivery composition of claim 1 , wherein a content of the temperature-sensitive hydrogel is from about 8 percentage by weight, and a content of the plurality of microbubbles is from about 1 percentage by weight to about 10 percentage by weight.

3. The drug delivery composition of claim 1 , wherein a particle diameter of each of the plurality of microbubbles is from about 0.5 μm to about 3.7 μm.

4. The drug delivery composition of claim 1 , wherein the drug is selected from the group consisting of steroid, anti-apoptotic drug, neurotrophic factor, growth factor, antibiotic, antioxidant, and a combination thereof.

5. A method for treating inner ear disorders, the method comprising administering to a subject in need thereof an effective amount of the drug delivery composition of claim 1 .

6. A method of manufacturing a drug delivery composition of claim 1 , the method comprising following steps:
mixing a microbubble material and a first solvent to form a first mixture;
treating the first mixture with an ultrasonic wave for about 100 seconds to 140 seconds to form a plurality of microbubbles, wherein each of the plurality of microbubbles has a protein shell and an inert gas core;
mixing a drug and a second solvent to form a second mixture;
mixing the second mixture and a temperature-sensitive hydrogel to form a temperature-sensitive drug hydrogel, wherein the temperature-sensitive hydrogel comprises poloxamer 407, a total weight of the drug delivery composition is 100 percentage by weight, and a content of the poloxamer 407 is no more than 12.5 percentage by weight; and
mixing the plurality of microbubbles and the temperature-sensitive drug hydrogel to form the drug delivery composition, wherein the drug delivery composition has a viscosity for inducing cavitation effect, the viscosity for inducing cavitation effect is from about 0.01 Pa·S to about 1.3846 Pa·S, and a gel-forming temperature of the drug delivery composition is greater than 25° C., and an amount of the plurality of microbubbles of the drug delivery composition is from about 1×10 8 to about 2×10 10 per mL.

7. The method of claim 6 , wherein the first solvent comprises saline.

8. The method of claim 6 , wherein the second solvent comprises dimethyl sulfoxide.

9. The method of claim 6 , wherein a content of the temperature-sensitive hydrogel is from about 8 percentage by weight, and a content of the plurality of microbubbles is from about 1 percentage by weight to about 10 percentage by weight.

10. The method of claim 6 , wherein a particle diameter of each of the plurality of microbubbles is from about 0.5 μm to about 3.7 μm.

11. The method of claim 6 , wherein the drug is selected from the group consisting of steroid, anti-apoptotic drug, neurotrophic factor, growth factor, antibiotic, antioxidant, and a combination thereof.

12. The drug delivery composition of claim 1 , wherein the gel-forming temperature of the drug delivery composition is smaller than 35° C.

13. A drug delivery composition, comprising:
a temperature-sensitive hydrogel, wherein the temperature-sensitive hydrogel comprises poloxamer 407, a total weight of the drug delivery composition is 100 percentage by weight, and a content of the poloxamer 407 is no more than 12.5 percentage by weight;
a plurality of microbubbles, wherein each of the plurality of microbubbles has a protein shell and an inert gas core, and the plurality of microbubbles are dispersed in the temperature-sensitive hydrogel, and an amount of the plurality of microbubbles of the drug delivery composition is from about 1×10 8 to about 2×10 10 per mL; and
a drug, dispersed in the temperature-sensitive hydrogel;
wherein the drug delivery composition has a viscosity for inducing cavitation effect of ultrasound before gel-forming and forms a fixed gel at a body temperature of a subject, the viscosity increases with increase of temperature, the drug delivery composition has a gel-forming temperature, the gel-forming temperature is greater than 25° C., and at a temperature range of 25° C. to 35° C., the viscosity has a range from 0.8029 Pa·S to 1.3846 Pa·S.

14. The drug delivery composition of claim 1 , wherein the content of the poloxamer 407 is more than about 10 percentage by weight.

15. The drug delivery composition of claim 13 , wherein a content of the temperature-sensitive hydrogel is from about 8 percentage by weight, and a content of the plurality of microbubbles is from about 1 percentage by weight to about 10 percentage by weight.

16. The drug delivery composition of claim 13 , wherein a particle diameter of each of the plurality of microbubbles is from about 0.5 μm to about 3.7 μm.

17. The drug delivery composition of claim 13 , wherein the drug is selected from the group consisting of steroid, anti-apoptotic drug, neurotrophic factor, growth factor, antibiotic, antioxidant, and a combination thereof.

18. The drug delivery composition of claim 13 , wherein the content of the poloxamer 407 is more than about 10 percentage by weight.

Assignees

• Univ Nat Taiwan Science & Technology
• Nat Defense Medical Center

Inventors

• Liao Ai-Ho
• Wang Chih-Hung
• Shih Cheng-Ping

Classifications

• A61K9/10

  Dispersions; Emulsions · CPC title

• A61K47/02 Primary

  Inorganic compounds · CPC title

• A61K47/42

  Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34) · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title